Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format |
| NEWS 3 | MAR 16 | CASREACT coverage extended |
| NEWS 4 | MAR 20 | MARPAT now updated daily |
| NEWS 5 | MAR 22 | LWPI reloaded |
| NEWS 6 | MAR 30 | RDISCLOSURE reloaded with enhancements |
| NEWS 7 | APR 02 | JICST-EPLUS removed from database clusters and STN |
| NEWS 8 | APR 30 | GENBANK reloaded and enhanced with Genome Project ID field |
| NEWS 9 | APR 30 | CHEMCATS enhanced with 1.2 million new records |
| NEWS 10 | APR 30 | CA/CAplus enhanced with 1870-1889 U.S. patent records |
| NEWS 11 | APR 30 | INPADOC replaced by INPADOCDB on STN |
| NEWS 12 | MAY 01 | New CAS web site launched |
| NEWS 13 | MAY 08 | CA/CAplus Indian patent publication number format defined |
| NEWS 14 | MAY 14 | RDISCLOSURE on STN Easy enhanced with new search and display fields |
| NEWS 15 | MAY 21 | BIOSIS reloaded and enhanced with archival data |
| NEWS 16 | MAY 21 | TOXCENTER enhanced with BIOSIS reload |
| NEWS 17 | MAY 21 | CA/CAplus enhanced with additional kind codes for German patents |
| NEWS 18 | MAY 22 | CA/CAplus enhanced with IPC reclassification in Japanese patents |
| NEWS 19 | JUN 27 | CA/CAplus enhanced with pre-1967 CAS Registry Numbers |
| NEWS 20 | JUN 29 | STN Viewer now available |
| NEWS 21 | JUN 29 | STN Express, Version 8.2, now available |
| NEWS 22 | JUL 02 | LEMBASE coverage updated |
| NEWS 23 | JUL 02 | LMEDLINE coverage updated |
| NEWS 24 | JUL 02 | SCISEARCH enhanced with complete author names |
| NEWS 25 | JUL 02 | CHEMCATS accession numbers revised |
| NEWS 26 | JUL 02 | CA/CAplus enhanced with utility model patents from China |

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

| | |
|---|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:41:23 ON 13 JUL 2007

=>
=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.21 | 0.21

FILE 'REGISTRY' ENTERED AT 13:41:33 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6
DICTIONARY FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s 257892-33-4
L1 1 257892-33-4
(257892-33-4/RN)

=> d str cn

L1 ANSWER 1 OF 1 REGISTRY 

F




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-

```
     fluorophenyl)methyl]-5-hydroxy-α-oxo-  (CA INDEX NAME)
OTHER NAMES:
CN   AWD 12-281
CN   GW 842470


=> file caplus medline embase biosis
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               2.85       3.06

FILE 'CAPLUS' ENTERED AT 13:42:50 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:42:50 ON 13 JUL 2007

FILE 'EMBASE' ENTERED AT 13:42:50 ON 13 JUL 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:42:50 ON 13 JUL 2007
Copyright (c) 2007 The Thomson Corporation

=> s 257892-33-4 or AWD 12-281
L2          111 257892-33-4 OR AWD 12-281

=> dup rem L2
PROCESSING COMPLETED FOR L2
L3           80 DUP REM L2 (31 DUPLICATES REMOVED)

=> s skin disease
L4       134945 SKIN DISEASE

=> s L3 and (AY<2003 or PY<2003 or PRY<2003)
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
   2 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
L5           36 L3 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> s topical
L6       261595 TOPICAL

=> s L5 and L6
L7            5 L5 AND L6

=> d 1-5 L7 ibib abs

L7   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:203704  CAPLUS
DOCUMENT NUMBER:          140:229455
TITLE:                    Combination of glucocorticoids and PDE-4-inhibitors
                          for treating respiratory diseases, allergic diseases,
                          asthma and COPD
INVENTOR(S):              Locher, Mathias; Hermann, Robert
PATENT ASSIGNEE(S):       Viatris G.m.b.H. & Co. K.-G., Germany
SOURCE:                   PCT Int. Appl., 26 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
```

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004019984 | A1 | 20040311 | WO 2003-EP8607 | 20030804 <-- |
| W: AU, BR, CA, CN, CO, CZ, GE, HR, ID, IL, IN, JP, KR, LT, LV, MD, MK, MX, NO, NZ, PL, SG, UA, US, UZ, YU, ZA | | | | |
| RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR | | | | |
| CA 2492645 | A1 | 20040311 | CA 2003-2492645 | 20030804 <-- |
| AU 2003255365 | A1 | 20040319 | AU 2003-255365 | 20030804 <-- |
| EP 1526870 | A1 | 20050504 | EP 2003-790851 | 20030804 <-- |
| EP 1526870 | B1 | 20070502 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1674939 | A | 20050928 | CN 2003-819057 | 20030804 <-- |
| JP 2005539042 | T | 20051222 | JP 2004-531853 | 20030804 <-- |
| AT 361076 | T | 20070515 | AT 2003-790851 | 20030804 <-- |
| US 2005288265 | A1 | 20051229 | US 2005-523802 | 20050209 <-- |
| IN 2005KN00155 | A | 20060421 | IN 2005-KN155 | 20050209 <-- |
| NO 2005001212 | A | 20050308 | NO 2005-1212 | 20050308 <-- |

| | | | | |
|---|---|---|---|---|
| PRIORITY APPLN. INFO.: | | | DE 2002-10236688 | A 20020809 <-- |
| | | | WO 2003-EP8607 | W 20030804 |

AB The invention relates to a novel combination of a glucocorticoid, especially loteprednol, and at least one phosphodiesterase-4 inhibitor (PDE-4-inhibitor), especially hydroxyindole-derivative N-(3,5-dichloropyridine-4-yl)-2-[1-(4-fluorbenzyl)-5-hydroxyindole-3-yl]-2-oxoacetamide, for a simultaneous, sequential or sep. administration in the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases (COPD). Formulation of glucocorticoids and PDE-4-inhibitors can be prepared sep. and applied at the same time or at different times during the day; also combinations can be formulated.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:60309 CAPLUS
DOCUMENT NUMBER: 140:105273
TITLE: Topical treatment of skin diseases
INVENTOR(S): Rundfeldt, Chris; Kietzmann, Manfred; Hoppmann, Joachim; Baeumer, Wolfgang; Kuss, Hildegard; Hoefgen, Norbert
PATENT ASSIGNEE(S): Elbion AG, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004006920 | A1 | 20040122 | WO 2003-EP7514 | 20030710 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, | | | | |

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | | |
|---|---|---|---|---|---|---|
| US | 2004038958 | A1 | 20040226 | US 2003-611649 | | 20030701 <-- |
| CA | 2492093 | A1 | 20040122 | CA 2003-2492093 | | 20030710 <-- |
| AU | 2003254332 | A1 | 20040202 | AU 2003-254332 | | 20030710 <-- |
| BR | 2003012696 | A | 20050426 | BR 2003-12696 | | 20030710 <-- |
| EP | 1531818 | A1 | 20050525 | EP 2003-763810 | | 20030710 <-- |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

| | | | | | | |
|---|---|---|---|---|---|---|
| CN | 1681500 | A | 20051012 | CN 2003-821520 | | 20030710 <-- |
| JP | 2005537262 | T | 20051208 | JP 2004-520586 | | 20030710 <-- |
| NZ | 537482 | A | 20060929 | NZ 2003-537482 | | 20030710 <-- |
| ZA | 2005000108 | A | 20050223 | ZA 2005-108 | | 20050106 <-- |
| NO | 2005000718 | A | 20050401 | NO 2005-718 | | 20050210 <-- |
| PRIORITY APPLN. INFO.: | | | | US 2002-395221P | P | 20020711 <-- |
| | | | | WO 2003-EP7514 | W | 20030710 |

OTHER SOURCE(S): MARPAT 140:105273

AB The present invention relates to a method for the treatment of an inflammatory and/or allergic skin disease comprising topically administering a substituted hydroxy indole which is a phosphodiesterase 4 inhibitor. Examples are provided of the topical effectiveness of AWD 12-281 and cilomilast in dermal immunol. inflammation.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:495906 CAPLUS
DOCUMENT NUMBER: 138:117605
TITLE: Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis
AUTHOR(S): Baumer, Wolfgang; Gorr, Gilbert; Hoppmann, Joachim; Ehinger, Andreas M.; Ehinger, Britt; Kietzmann, Manfred
CORPORATE SOURCE: Toxicology and Pharmacy, Department of Pharmacology, School of Veterinary Medicine, Hanover, 30559, Germany
SOURCE: European Journal of Pharmacology (2002), 446(1-3), 195-200
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The inhibitors of the phosphodiesterase 4, SB 207499 (cilomilast, c-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-r-L-cyclohexane carboxylic acid) and AWD 12-281 (N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindole-3-yl]glyoxylic acid amide) were tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate. The allergic reaction was challenged by topical administration of toluene-2,4-diisocyanate onto the mice ears. Before challenge, two groups of mice were treated topically (ear skin) with SB 207499 or AWD 12-281. There was a significant ear swelling in toluene-2,4-diisocyanate-challenged mice ears 4, 8, 16, 24 and 48 h after challenge. SB 207499 and AWD 12-281 inhibited this swelling significantly 8, 16, 24 and 48 h after the challenge. For biochem. parameters and histol., ears were sampled from mice sacrificed 4, 8 and 16 h after the challenge. In homogenized tissue, SB 207499 and AWD 12-281 inhibited significantly the secretion of interleukin 1β induced by toluene-2,4-diisocyanate 4 and 8 h after challenge. The cell influx (granulocytes) observed in the toluene-2,4-diisocyanate-challenged mice 8 and 16 h after challenge was nearly abolished by AWD 12-

281 and SB 204799.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:420229 CAPLUS
DOCUMENT NUMBER: 138:18980
TITLE: AWD 12-281
AUTHOR(S): Kuss, H.; Hofgen, N.; Egerland, U.; Heer, S.; Marx, D.; Szelenyi, I.; Schupke, H.; Gasparic, A.; Olbrich, M.; Hempel, R.; Hartenhauer, H.; Krone, D.; Berthold, K.; Kronbach, T.; Rundfeldt, C.
CORPORATE SOURCE: Arzneimittelwerk Dresden GmbH, Radebeul, D-01445, Germany
SOURCE: Drugs of the Future (2002), 27(2), 111-116
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Airway diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory diseases whose prevalence is increasing. Current research concerned with developing effective treatments for these conditions have focused on the search for alternatives to the standard corticosteroid antiinflammatory therapy. Selective phosphodiesterase 4 (PDE4) inhibitors have received a considerable amount of attention due to their ability to suppress the functions of several cell types involved in allergic and inflammatory disorders. The selective PDE4 inhibitor AWD 12-281 is the result of a pharmacophore-based synthesis program wherein the optimization process was supported by ligand-based drug design methods. AWD 12-281 was selected for further development for its high affinity and selectivity for the human PDE4 isoenzyme and due to its potent activity and excellent tolerability in models of allergic rhinitis, asthma and COPD, especially after topical treatment.
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2000413538 EMBASE
TITLE: Animal models of allergic rhinitis.
AUTHOR: Szelenyi I.; Marx D.; Jahn W.
CORPORATE SOURCE: Dr. I. Szelenyi, Pulmonary Pharmacology (BF-FP2), Meissnerstr. 191, 01445 Radebeul, Germany. stefan.szelenyi@astamedica.de
SOURCE: Arzneimittel-Forschung/Drug Research, (2000) Vol. 50, No. 11, pp. 1037-1042. .
Refs: 44
ISSN: 0004-4172 CODEN: ARZNAD
COUNTRY: Germany
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 011 Otorhinolaryngology
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English; German
ENTRY DATE: Entered STN: 14 Dec 2000
Last Updated on STN: 14 Dec 2000
AB Actively sensitized Brown Norway rats and guinea pig are useful species for studying drug effects on symptoms of experimental rhinitis. Even if not all symptoms of human rhinitis can be induced and detected in the same animal species, the predictablity of methods generally used is well

acceptable. In the present review, advantages and disadvantages of experimental methods of rhinitis will be discussed.

```
=> s dermal or skin
L8      1414890 DERMAL OR SKIN

=> s L3 and L8
L9            13 L3 AND L8

=> d 1-13 ibib abs

L9   ANSWER 1 OF 13  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:331227  CAPLUS
DOCUMENT NUMBER:          146:308239
TITLE:                    Highly selective phosphodiesterase 4 inhibitors for
                          the treatment of allergic skin diseases and
                          psoriasis
AUTHOR(S):                Baeumer, Wolfgang; Hoppmann, Joachim; Rundfeldt,
                          Chris; Kietzmann, Manfred
CORPORATE SOURCE:         Department of Pharmacology, Toxicology, and Pharmacy,
                          Foundation, University of Veterinary Medicine
                          Hannover, Hannover, D-30559, Germany
SOURCE:                   Inflammation & Allergy: Drug Targets (2007), 6(1),
                          17-26
                          CODEN: IADTAQ; ISSN: 1871-5281
PUBLISHER:                Bentham Science Publishers Ltd.
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 English
AB   A review. The phosphodiesterase (PDE) 4 is the predominant cAMP degrading
     enzyme in a variety of inflammatory cells including eosinophils,
     neutrophils, macrophages, T cells and monocytes. In addition, this enzyme is
     expressed in non-immune cells such as keratinocytes and fibroblasts.
     Highly selective PDE4 inhibitors are currently under evaluation for the
     treatment of asthma and/or chronic obstructive pulmonary disease. Due to
     the broad anti-inflammatory/immunomodulatory action of PDE4 inhibitors, it
     has been proposed that PDE4 inhibitors might also be efficacious for
     skin disorders such as atopic dermatitis. Consequently, PDE4
     inhibitors including cilomilast and AWD 12-281
     have been tested in several models of allergic and irritant skin
     inflammation. These PDE4 inhibitors displayed strong anti-inflammatory
     action in models of allergic contact dermatitis in mice, in the
     arachidonic acid induced skin inflammation in mice and in
     ovalbumin sensitized guinea pigs. The determination of cytokines in skin
     homogenates revealed that both Th1 as well as Th2 cytokines are suppressed
     by PDE4 inhibitors, indicating an anti-inflammatory activity in both the
     Th2 dominated acute phase as well as the Th1 dominated chronic phase of
     atopic dermatitis. Due to the suppression of Th1 cytokines, activity can
     also be expected in psoriasis. Results of early clin. trials with both
     topically (cipamfylline, CP80,633) and systemically (CC-10004) active PDE4
     inhibitors demonstrated efficacy in atopic dermatitis and in the case of
     CC-10004, also in psoriasis. AWD 12-281 (GW
     842470) is currently under clin. evaluation for the topical treatment of
     atopic dermatitis. Results concerning clin. efficacy of this potent and
     selective PDE4 inhibitor are anxiously awaited.
REFERENCE COUNT:          50    THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 2 OF 13  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1256669  CAPLUS
DOCUMENT NUMBER:          146:20293
TITLE:                    Novel medicament combinations for the treatment of
                          respiratory diseases
INVENTOR(S):              Pieper, Michael P.; Schnapp, Andreas; Nickolaus, Peter
```

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 33pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2006270667 | A1 | 20061130 | US 2006-420872 | 20060530 |
| WO 2006128847 | A2 | 20061207 | WO 2006-EP62683 | 20060529 |
| WO 2006128847 | A3 | 20070426 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2005-104702 A 20050531
OTHER SOURCE(S): MARPAT 146:20293

AB The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, betamimetic, at least one anticholinergic and at least one PDE-IV inhibitor processes for preparing them and their use as pharmaceutical compns.

L9 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:365169 CAPLUS
DOCUMENT NUMBER: 144:419682
TITLE: Pharmaceutical compositions containing phosphodiesterase IV inhibitors and immunosuppressants
INVENTOR(S): Harada, Daisuke; Kobayashi, Katsuya; Manabe, Haruhiko; Ohshima, Etsuo
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006041120 | A1 | 20060420 | WO 2005-JP18854 | 20051013 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

| | | | | |
|---|---|---|---|---|
| CA 2584261 | A1 | 20060420 | CA 2005-2584261 | 20051013 |

PRIORITY APPLN. INFO.: JP 2004-299104 A 20041013

JP 2005-113265 A 20050411
WO 2005-JP18854 W 20051013

AB This invention relates to pharmaceutical compns. for the prevention and treatment of chronic skin diseases, comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacol. acceptable salt thereof and (b) an immunosuppressant, which are administered simultaneously or sep. with an interval. For example, tablets were formulated containing 2-(3,5-dichloro-4-pyridinyl)-1-(7-methoxyspiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)ethanone (PDE-IV inhibitor) 20, tacrolimus (immunosuppressant) 20, lactose 123.4, starch 20, hydroxypropyl cellulose 6, and Mg stearate 0.6 mg per tablet.

REFERENCE COUNT: 113 THERE ARE 113 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:364924 CAPLUS
DOCUMENT NUMBER: 144:398341
TITLE: Phosphodiesterase IV inhibitor and steroid combinations for the treatment of chronic skin disease
INVENTOR(S): Harada, Daisuke; Kobayashi, Katsuya; Manabe, Haruhiko; Ohshima, Etsuo
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006041121 | A1 | 20060420 | WO 2005-JP18855 | 20051013 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| CA 2584169 | A1 | 20060420 | CA 2005-2584169 | 20051013 |

PRIORITY APPLN. INFO.: JP 2004-299103 A 20041013
JP 2005-113264 A 20050411
WO 2005-JP18855 W 20051013

AB It is intended to provide a remedy and/or a preventive for a chronic skin disease which comprises (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacol. acceptable salt thereof and (b) a steroid drug, which are administered simultaneously or sep. at an interval. For example, tablets were formulated containing 2-(3,5-dichloro-4-pyridinyl)-1-(7-methoxyspiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)ethanone 50, prednisolone 20, lactose 123.4, starch 20, hydroxypropyl cellulose 6, and Mg stearate 0.6 mg per tablet.

REFERENCE COUNT: 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:226501 CAPLUS

DOCUMENT NUMBER: 144:267237
TITLE: The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice
AUTHOR(S): Hoppmann, Joachim; Baeumer, Wolfgang; Galetzka, Christin; Hoefgen, Norbert; Kietzmann, Manfred; Rundfeldt, Chris
CORPORATE SOURCE: Department of Pharmacology, elbion AG, Radebeul, D-01445, Germany
SOURCE: Journal of Pharmacy and Pharmacology (2005), 57(12), 1609-1617
CODEN: JPPMAB; ISSN: 0022-3573
PUBLISHER: Pharmaceutical Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The selective phosphodiesterase 4 (PDE4) inhibitor AWD 12-281 is structurally optimized for topical administration. It has potent effects in models of lung inflammation if administered as a dry powder inhalation. It has also demonstrated its anti-inflammatory property in a mouse model of cutaneous inflammation after topical administration. The aim of this study was to evaluate whether AWD 12-281 may be capable of penetrating human skin. Therefore a new guinea-pig model of allergic skin inflammation had to be developed. In ovalbumin-sensitized guinea-pigs, intracutaneous administration of ovalbumin results in a rapid development of allergic skin wheals. Topically administered AWD 12-281 was capable of reducing the development of wheals, indicating that this compound can penetrate the stratum corneum of guinea-pig skin as a predictor of human skin penetration. A secondary aim was the evaluation of a T cell subtype preference of AWD 12-281 since PDE4 inhibitors are said to preferentially inhibit Th2-type cytokines. Therefore, the effects of AWD 12-281 on a broad spectrum of Th1- and Th2-type cytokines were studied in tissue homogenates after allergen challenge in sensitized mice and in supernatants of anti CD3/anti-CD28-stimulated peripheral blood mononuclear cells (PBMCs). In both models, AWD 12-281 suppressed both T cell subtype cytokines indicating a broad spectrum activity of AWD 12-281. A further issue was to determine the duration of action and the concentration-response relation of the topical activity of AWD 12-281 using a model of acute local inflammation - the arachidonic-acid-induced mouse ear edema. The compound exhibited a dose-dependent effect with a minimally effective concentration of 0.3%; after repeated administration the minimally effective concentration was 0.03%. A single administration of a 3% solution resulted in significant suppression of inflammation even 48 h after treatment. In conclusion, our results indicate that AWD 12-281 is a very promising drug candidate not only for the treatment of lung inflammation using inhalative administration but also for the treatment of atopic dermatitis.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:149262 CAPLUS
DOCUMENT NUMBER: 144:239931
TITLE: Pharmaceutical compositions for the treatment of respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit; Himmelsbach, Frank
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG

SOURCE: PCT Int. Appl., 321 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006015775 | A2 | 20060216 | WO 2005-EP8385 | 20050803 |
| WO 2006015775 | A3 | 20070518 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

| | | | | |
|---|---|---|---|---|
| US 2006035893 | A1 | 20060216 | US 2005-189643 | 20050726 |
| CA 2575541 | A1 | 20060216 | CA 2005-2575541 | 20050803 |
| EP 1784224 | A2 | 20070516 | EP 2005-773706 | 20050803 |

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | EP 2004-18808 | A | 20040807 |
| | WO 2005-EP8385 | W | 20050803 |

OTHER SOURCE(S): MARPAT 144:239931

AB The present invention relates to novel pharmaceutical compns. comprising at least 1 EGFR kinase inhibitor and at least one addnl. active compound selected from β-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for preparing the compns. and the use thereof as drugs in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes. Thus, an inhalable powder contained an EGFR kinase inhibitor 150, formoterol fumarate dihydrate 50, and lactose 12,300 mg/capsule.

L9 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1155523 CAPLUS
DOCUMENT NUMBER: 143:416252
TITLE: Novel medicament combinations for the treatment of respiratory diseases
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 50 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2005239778 | A1 | 20051027 | US 2005-109094 | 20050419 |
| DE 102004019540 | A1 | 20051110 | DE 2004-102004019540 | 20040422 |
| DE 102004052987 | A1 | 20060504 | DE 2004-102004052987 | 20041103 |
| AU 2005235419 | A1 | 20051103 | AU 2005-235419 | 20050418 |
| CA 2559699 | A1 | 20051103 | CA 2005-2559699 | 20050418 |
| WO 2005102349 | A1 | 20051103 | WO 2005-EP4073 | 20050418 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| EP 1781298 | A1 | 20070509 | EP 2005-739576 | 20050418 |
| NO 2006005060 | A | 20061121 | NO 2006-5060 | 20061102 |

PRIORITY APPLN. INFO.:

| | |
|---|---|
| DE 2004-102004019540A | 20040422 |
| US 2004-578542P P | 20040610 |
| DE 2004-102004052987A | 20041103 |
| EP 2005-2496 A | 20050207 |
| WO 2005-EP4073 W | 20050418 |

OTHER SOURCE(S): MARPAT 143:416252

GI



I

AB The present invention relates to a pharmaceutical composition comprising one or more compds. of formula I wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R3 denotes C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, and at least one other active substance for the treatment of respiratory diseases. The second active substance can by an anticholinergic, a phosphodiesterase IV inhibitor, a steroid, a LTD4 antagonist or an EGFR inhibitor.

L9 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:60309 CAPLUS
DOCUMENT NUMBER: 140:105273
TITLE: Topical treatment of skin diseases
INVENTOR(S): Rundfeldt, Chris; Kietzmann, Manfred; Hoppmann, Joachim; Baeumer, Wolfgang; Kuss, Hildegard; Hoefgen, Norbert
PATENT ASSIGNEE(S): Elbion AG, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004006920 | A1 | 20040122 | WO 2003-EP7514 | 20030710 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| US | 2004038958 | A1 | 20040226 | US 2003-611649 | 20030701 |
| CA | 2492093 | A1 | 20040122 | CA 2003-2492093 | 20030710 |
| AU | 2003254332 | A1 | 20040202 | AU 2003-254332 | 20030710 |
| BR | 2003012696 | A | 20050426 | BR 2003-12696 | 20030710 |
| EP | 1531818 | A1 | 20050525 | EP 2003-763810 | 20030710 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

| | | | | | |
|---|---|---|---|---|---|
| CN | 1681500 | A | 20051012 | CN 2003-821520 | 20030710 |
| JP | 2005537262 | T | 20051208 | JP 2004-520586 | 20030710 |
| NZ | 537482 | A | 20060929 | NZ 2003-537482 | 20030710 |
| ZA | 2005000108 | A | 20050223 | ZA 2005-108 | 20050106 |
| NO | 2005000718 | A | 20050401 | NO 2005-718 | 20050210 |

PRIORITY APPLN. INFO.: US 2002-395221P P 20020711
WO 2003-EP7514 W 20030710

OTHER SOURCE(S): MARPAT 140:105273

AB The present invention relates to a method for the treatment of an inflammatory and/or allergic skin disease comprising topically administering a substituted hydroxy indole which is a phosphodiesterase 4 inhibitor. Examples are provided of the topical effectiveness of AWD 12-281 and cilomilast in dermal immunol. inflammation.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:695438 CAPLUS
DOCUMENT NUMBER: 140:87294
TITLE: AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis
AUTHOR(S): Baeumer, Wolfgang; Gorr, Gilbert; Hoppmann, Joachim; Ehinger, Andreas M.; Rundfeldt, Chris; Kietzmann, Manfred
CORPORATE SOURCE: Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Hannover, D-30559, Germany
SOURCE: Journal of Pharmacy and Pharmacology (2003), 55(8), 1107-1114
CODEN: JPPMAB; ISSN: 0022-3573
PUBLISHER: Pharmaceutical Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB AWD 12-281 (N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide), a phosphodiesterase 4 inhibitor, which is optimized for topical administration, was tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate (TDI). The allergic reaction was challenged by topical administration of TDI onto the mice ears. AWD 12-281 was tested for its anti-inflammatory potential by oral, i.p. and topical administration. The phosphodiesterase 4 inhibitor, cilomilast (SB 207499), and/or the corticosteroid, diflorasone diacetate, were used as reference compds. Given orally and i.p. 2 h before as well as 5

and 24 h after TDI challenge, AWD 12-281 showed no, or only a transient inhibition of the allergen-induced ear swelling, whereas cilomilast significantly inhibited this ear swelling. Applied topically onto the ears before TDI challenge, AWD 12-281, cilomilast and diflorasone diacetate caused total inhibition of ear swelling 24 h after challenge, confirmed by a decrease of the pro-inflammatory cytokines interleukin-4, interleukin-6 and macrophage inhibitory protein-2. Administered topically after TDI challenge as therapeutic intervention, AWD 12-281 and diflorasone diacetate caused significant inhibition of ear swelling; cilomilast failed to do so. These results indicate that topically administered AWD 12-281 may be potent in the prevention and treatment of allergic/inflammatory skin diseases.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:495906 CAPLUS
DOCUMENT NUMBER: 138:117605
TITLE: Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis
AUTHOR(S): Baumer, Wolfgang; Gorr, Gilbert; Hoppmann, Joachim; Ehinger, Andreas M.; Ehinger, Britt; Kietzmann, Manfred
CORPORATE SOURCE: Toxicology and Pharmacy, Department of Pharmacology, School of Veterinary Medicine, Hanover, 30559, Germany
SOURCE: European Journal of Pharmacology (2002), 446(1-3), 195-200
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The inhibitors of the phosphodiesterase 4, SB 207499 (cilomilast, c-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-r-L-cyclohexane carboxylic acid) and AWD 12-281 (N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindole-3-yl]glyoxylic acid amide) were tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate. The allergic reaction was challenged by topical administration of toluene-2,4-diisocyanate onto the mice ears. Before challenge, two groups of mice were treated topically (ear skin) with SB 207499 or AWD 12-281. There was a significant ear swelling in toluene-2,4-diisocyanate-challenged mice ears 4, 8, 16, 24 and 48 h after challenge. SB 207499 and AWD 12-281 inhibited this swelling significantly 8, 16, 24 and 48 h after the challenge. For biochem. parameters and histol., ears were sampled from mice sacrificed 4, 8 and 16 h after the challenge. In homogenized tissue, SB 207499 and AWD 12-281 inhibited significantly the secretion of interleukin 1β induced by toluene-2,4-diisocyanate 4 and 8 h after challenge. The cell influx (granulocytes) observed in the toluene-2,4-diisocyanate-challenged mice 8 and 16 h after challenge was nearly abolished by AWD 12-281 and SB 204799.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 13 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2007223472 EMBASE
TITLE: Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

AUTHOR: Dastidar S.G.; Rajagopal D.; Ray A.
CORPORATE SOURCE: S.G. Dastidar, Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Gurgaon 122 001, India. sunanda.dastidar@ranbaxy.com
SOURCE: Current Opinion in Investigational Drugs, (2007) Vol. 8, No. 5, pp. 364-372. .
Refs: 101
ISSN: 1472-4472 CODEN: CIDREE
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 5 Jun 2007
Last Updated on STN: 5 Jun 2007

AB Intracellular levels of cyclic nucleotides are closely regulated by distinct families of PDEs, which are responsible for the breakdown and degradation of cyclic nucleotides within cells. Type 4 PDEs have the potency to modulate the release of inflammatory mediators through cAMP-dependent and -independent mechanisms. Selective targeting of PDE4 is currently being investigated as a novel therapeutic approach in the treatment of inflammation-associated respiratory diseases such as asthma and COPD. The development of several PDE4 inhibitors, including roflumilast and cilomilast, reflects the success of this approach. In principle, therapeutic intervention of an inflammatory response by PDE4 inhibitors may be extended to other chronic inflammatory disease states such as psoriasis, rheumatoid arthritis and inflammatory bowel diseases (eg, Crohn's disease and ulcerative colitis). This review explores the feasibility of PDE4 inhibitors as a promising alternative for therapeutic intervention in systemic inflammation and inflammation-based disease.


L9 ANSWER 12 OF 13 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:307114 BIOSIS
DOCUMENT NUMBER: PREV200300307114
TITLE: The phosphodiesterase 4 inhibitors AWD 12 -281 and cilomilast exhibit different effectiveness in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
AUTHOR(S): Baeumer, W. [Reprint Author]; Hoppmann, J.; Tschernig, T.; Seegers, U. [Reprint Author]; Rundfeldt, C.; Kietzmann, M. [Reprint Author]
CORPORATE SOURCE: Depts of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, 30559, Hannover, Germany
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology, (March 2003) Vol. 367, No. Supplement 1, pp. R77. print.
Meeting Info.: 44th Spring Meeting of the Deutsche Gesellschaft fuer Experimentelle und Klinische Pharmakologie und Toxikologie and the 20th Meeting of the Gesellschaft fuer Umwelt-Mutationsforschung. Mainz, Germany. March 17-20, 2003.
ISSN: 0028-1298 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Jul 2003
Last Updated on STN: 2 Jul 2003

L9 ANSWER 13 OF 13 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:297031 BIOSIS

DOCUMENT NUMBER: PREV200100297031
TITLE: Studies with AWD 12281 in the skin of sensitized mice.
AUTHOR(S): Ehinger, A. M. [Reprint author]; Gorr, G. [Reprint author]; Hoppmann, J. [Reprint author]; Telser, E. [Reprint author]; Kietzmann, M. [Reprint author]
CORPORATE SOURCE: Institut fuer Pharmakologie, Toxikologie und Pharmazie, Tieraerztliche Hochschule Hannover, Buenteweg 17, D-30559, Hannover, Germany
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology, (2001) Vol. 363, No. 4 Supplement, pp. R85. print.
Meeting Info.: 42nd Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology. Mainz, Germany. March 13-15, 2001. German Society for Experimental and Clinical Pharmacology and Toxicology.
CODEN: NSAPCC. ISSN: 0028-1298.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Jun 2001
Last Updated on STN: 19 Feb 2002